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interval to surgery is a promising treatment because the 
pathological complete response (pCR) rate of over 20% was 
recorded. The body of evidence from studies that used 
conventionally fractionated radiochemotherapy showed that, 
with a longer interval to surgery, the pCR rate and 
downstaging increased, whereas the R0 resection rate, the 
sphincter preservation rate and the long-term oncological 
outcomes remained much the same. 
The desired effect of radiation, namely irreparable DNA 
damage which ceased clonogens division, occurs at the time 
of irradiation. A lengthening of the interval between 
radio(chemo)therapy and surgery does not produce additional 
DNA damage. With delayed surgery, there is a risk of tumour 
regrowth and the development of a cancer phenotype that 
produces distant metastases. Indeed evaluation of a labelling 
index showed the accelerated proliferation of cancer cells in 
some tumours one month after 5 x 5 Gy. PET/CT 
examinations demonstrated increased metabolic activity in 
some tumours between 6 and 12 weeks after chemoradiation. 
Thus, the long interval potentially jeopardizes oncological 
outcomes in up-front resectable cancers. This effect, 
however, was not shown in the randomized studies or in the 
meta-analysis.  
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Purpose/Objective: In patients with rectal cancer 
(chemo)radiotherapy is usually followed by low anterior 
resection (LAR) or abdominoperineal resection (APR) with 
permanent colostomy. Type of surgery depends on tumor 
localization, patient's condition and surgeons' preference. 
Until now, there is still debate which procedure is superior in 
terms of quality of life (QoL). In this study we compare QoL 
during the first six months of treatment in patients 
undergoing LAR and APR. 
Materials and Methods: This study was performed in the 
context of the ProspectIve data CollectioN Iniative on 
Colorectal cancer (PICNIC) cohort. Within PICNIC patients fill 
out standardized QoL questionnaires at start of radiotherapy 
and every 3 months thereafter. In the present study, 
participants with rectal cancer who underwent curative 
surgery following radiotherapy between February 2013 and 
September 2014 were included. QoL was measured by means 
of EORTC QLQ-C30 and CR29, at baseline, 3 and 6 months. 
Responses were transformed to a longitudinal scale and 
reported as mean or median, depending on distribution. Mean 
differences in QoL scores were calculated and categorized as 
improved, stable and worsened. Differences in QoL were 
tested on significance with the Mann-Whitney U test and Chi-
square test. 
Results: One-hundred-fourteen patients were identified, 55 
(48%) underwent APR and 59 (52%) LAR. Baseline 
characteristics between were similar for both groups, except 
for tumor location (90.9% vs. 28.8% located in lower third of 
the rectum for APR and LAR resp.) and T-stage (66.7% vs. 
83.1% T3 tumors for APR and LAR resp.). At baseline, LAR 
patients reported a higher mean score for physical function 
(90 vs. 82, p= 0.008), role function (84 vs. 72, p= 0.008) and 
global health (75 vs. 66, p= 0.013) compared to APR patients. 
After 3 months, both groups reported similar differences in 
QoL function scales. At 6 months, global health recovered in 
APR patients to baseline levels or above (only 22.6% reported 
to worsen compared to baseline), while LAR patients showed 
slower recovery (with 43.5% worsened status). At 6 months, 
APR patients had worsened body image compared to LAR 
patients (mean difference -19 (-26.7 to -11.3) vs. -11 (15.8 to 
-6.8), p=0.01), but improved stool frequency (mean 
difference +18 (7.9 to 28.8) resp. -6 (-15.4 to 3.9) p=0.003). 
Regarding symptoms, LAR patients worsened on 
embarrassment for defecation pattern, while APR patients 
worsened on urine incontinence and impotence. 
Conclusions: The impact of surgery type on QoL during the 
first six months in rectal cancer patients pretreated with 
(chemo)radiation is similar for most domains. However, 
patients who underwent APR seem to recover more quickly in 
respective of their global QoL before treatment. Symptom 
patterns were quite different between patients undergoing 
LAR or APR. These results can be helpful in counseling 
patients in treatment choice, giving the large differences in 
patients' perspective, lifestyle, and expectations of 
treatment. 
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Purpose/Objective: To present an interim analysis of the 
trial of concurrent capecitabine and radiotherapy with or 
without oxaliplatin as adjuvant treatment for locally 
advanced rectal cancer.  
Materials and Methods: This was a multicentre, open-label, 
randomized, phase 3 study in patients with pathological stage 
II-III rectal cancer. Patients were randomized to either 
radiotherapy 45-50.4 Gy/25-28 fractions with concurrent 
capecitabine 1600 mg/m2 on days 1-14, 22-35 (Cap-RT group) 
or 45-50.4 Gy/25-28 fractions with capecitabine 1300 mg/m2 
on days 1-14, 22-35 and oxaliplatin 60 mg/m2 on weeks 1, 2, 
4, 5 (Capox-RT group). Randomization was done with 
computer-generated block-randomization codes stratified by 
centre and pathological stage (II vs. III) without masking. The 
primary endpoint was 3-year disease-free survival rate (DFS); 
secondary endpoints included overall survival rate (OS), 
locoregional failure free survival rate (LRFFS), distant 
metastasis free survival rate (DMFS), compliance, and safety. 
Safety and compliance analyses included patients as treated, 
efficacy endpoints were analysed according to the intention-
to-treat principle. This study is registered with 
ClinicalTrials.gov, number NCT00714077. 
Results: Providing 80% power to detect an increase of 3y-DFS 
from 65% to 75% (α=0.05, 2-tailed test), 570 patients were 
required. Between January 2008 and July 2014, 492 patients 
were recruited from 4 centers in China. Of these patients, 
478 were evaluable (254 in the Cap-RT group and 224 in the 
Capox-RT group), with a median follow-up of 34.6 months for 
patients alive. The 3-year DFS rate was 71.6% in the Capox-
RT group, as compared with 73.9% in the Cap-RT group (p= 
0.647). No statistically significant difference was observed in 
OS, LRFFS, and DMFS between the two groups (3-year OS: 
88.1% vs. 85.4%, p = 0.770; LRFFS: 91.9% vs. 96.1%, p = 0.079; 
DMFS: 76.1% vs. 74.3%, p = 0.934), but higher cumulative 
locoregional recurrence rate in the Cap-RT group (6.7% vs. 
